Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Reata Pharma (RETA)
Reata Pharma (RETA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,575,535
  • Shares Outstanding, K 38,150
  • Annual Sales, $ 2,220 K
  • Annual Income, $ -311,900 K
  • 60-Month Beta 1.42
  • Price/Sales 2,966.61
  • Price/Cash Flow N/A
  • Price/Book 74.73
Trade RETA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.62
  • Most Recent Earnings $-2.32 on 08/08/23
  • Latest Earnings Date 11/14/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 3.83%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -2.15
  • Number of Estimates 3
  • High Estimate -1.89
  • Low Estimate -2.30
  • Prior Year -2.16
  • Growth Rate Est. (year over year) +0.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.67 +2.19%
on 09/05/23
172.46 -0.06%
on 09/25/23
+3.36 (+1.99%)
since 08/25/23
3-Month
88.80 +94.10%
on 06/27/23
172.46 -0.06%
on 09/25/23
+78.57 (+83.77%)
since 06/23/23
52-Week
21.83 +689.56%
on 10/11/22
172.46 -0.06%
on 09/25/23
+150.24 (+679.20%)
since 09/23/22

Most Recent Stories

More News
Is Biogen Stock a Buy Now?

It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.

BIIB : 220.20 (+1.48%)
RETA : 172.36 (+0.02%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, TRHC, VRTV, CTG

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RETA : 172.36 (+0.02%)
TRHC : 10.50 (+0.86%)
VRTV : 169.99 (+0.02%)
CTG : 10.50 (+0.10%)
3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry...

BIIB : 220.20 (+1.48%)
REGN : 984.47 (+1.90%)
RETA : 172.36 (+0.02%)
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?

Buying a biotech is a good move, but it might not be enough to entice investors.

BIIB : 220.20 (+1.48%)
RETA : 172.36 (+0.02%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, NEWR, RETA, AMNB

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SOVO : 22.78 (-0.04%)
NEWR : 86.99 (+0.02%)
RETA : 172.36 (+0.02%)
AMNB : 44.59 (-1.17%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCF, SCU, AMNB, RETA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CCF : 127.49 (+0.04%)
SCU : 12.72 (-0.24%)
AMNB : 44.59 (-1.17%)
RETA : 172.36 (+0.02%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CELL, AEL, RETA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CELL : 0.9981 (+0.31%)
AEL : 55.61 (+0.13%)
RETA : 172.36 (+0.02%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, NEWR, RETA, SOVO

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AMNB : 44.59 (-1.17%)
NEWR : 86.99 (+0.02%)
RETA : 172.36 (+0.02%)
SOVO : 22.78 (-0.04%)
Housing, Retail Figures Due Next Week

Housing, Retail Figures Due Next Week Monday U.S. Featured Earnings Roivant (NASDAQ: ...

BLX.TO : 30.00 (+0.55%)
CJT.TO : 111.63 (+0.81%)
PBH.TO : 89.79 (+0.07%)
ROIV : 11.65 (+1.84%)
MNDY : 221.94 (-0.48%)
RETA : 172.36 (+0.02%)
HD : 383.76 (+0.83%)
A : 137.27 (-0.07%)
SE : 50.67 (+4.43%)
CSCO : 48.03 (-0.70%)
TJX : 99.02 (-0.12%)
SNPS : 587.49 (+2.40%)
With an Acquisition on the Way, Is Biogen Stock a Buy?

Can the biotech finally get back in the good graces of investors?

RETA : 172.36 (+0.02%)
BIIB : 220.20 (+1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates...

See More

Key Turning Points

3rd Resistance Point 172.58
2nd Resistance Point 172.52
1st Resistance Point 172.44
Last Price 172.36
1st Support Level 172.30
2nd Support Level 172.24
3rd Support Level 172.16

See More

52-Week High 172.46
Last Price 172.36
Fibonacci 61.8% 114.92
Fibonacci 50% 97.15
Fibonacci 38.2% 79.37
52-Week Low 21.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar